This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New York State Department Of Health Issues Clinical Laboratory Permit To Empire Genomics

BUFFALO, N.Y., Nov. 12, 2013 /PRNewswire/ -- Empire Genomics, LLC ( www.empiregenomics.com), an emerging molecular diagnostics company in the field of personalized medicine, announced today that its clinical laboratory facility has met the rigorous standards and obtained approval by the New York State Department of Health, and is now fully licensed (#PFI 8680) in Cytogenetics-Cancer. Simultaneously, Empire Genomics' lab received Clinical Laboratory Improvements Amendments (CLIA) certification of registration (#33D2043745) from the Centers for Medicare and Medicaid Services (CMS).

(Logo:  http://photos.prnewswire.com/prnh/20131112/PH14865LOGO)

Empire Genomics' new clinical capabilities allow it to work closer with its' biotech clients to launch Laboratory Developed Test (LDT) companion diagnostics. With the recent announcement of two biomarkers identified in myeloma and prostate cancers, they are slated to offer these biomarkers as CLIA LDT assays in 2014. This is further validation of the high quality standards Empire continues to meet in the delivery of its testing services.

"This is yet another important asset to our business and one that we are extremely proud to have obtained.  It is a testament to the highly skilled and dedicated staff that we have at the Company which permits our expansion of complete genomic testing services to our clients," says Anthony Johnson, Empire Genomics President and CEO.

Dr. Theresa Brown, Clinical Lab Director at Empire Genomics, expressed "We are thrilled to have received our New York State laboratory permit so we can begin providing our high quality of testing on clinical samples."

Empire Genomics will continually seek to add new tests and technologies to its menu as it deems necessary and appropriate to deliver comprehensive personalized medicine services to its customers. 

About Empire Genomics  Empire Genomics, LLC is a molecular diagnostics firm specializing in oncology. The company offers a wide range of best-in-class services that are used to detect genomic changes. The organization is a global leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, prognosis, and selection of ideal disease therapy.

Media Contact:

Sonya Stutts  Phone: 716.856.3873  Email

Read more news from Empire Genomics

SOURCE Empire Genomics, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs